I believe the most likely reason Cyrus is coming back with a different executive title is because the current President is actually a CFO . If there is negotiations for a partner to come in and help finance trials or ? Cyrus is the one that speaks “Pharma” and needs to be at the forefront of those discussions , not the current Pres. the fact he doesn’t have the CEO title says they are looking at hiring a CEO as an option but I doubt if that is the only option they are reviewing. It could also mean they are going to execute a deal with another Pharma as an option here ..my guess is the Board Chairman is the primary in calling the shots here , not the president and not Cyrus... that’s obviously my opinion but I’m trying to fill in the BLANKS and this to me, is the most logical approach.